Skip to content
DataLookout
Menu

NCT04722523

A Study of Cemiplimab With Chemotherapy and Immunotherapy in People With Head and Neck Cancer

StatusRecruiting
PhasePhase 1
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

Version history last read from ClinicalTrials.gov on Aug 31, 2026. The record was updated there on Nov 20, 2026; versions filed since then are not listed here yet.

All 21 versions: 13 with changes below, 8 re-verified with no change. See every version on ClinicalTrials.gov ↗

  1. Minor Trial arms changed: 2 → 3
  2. Notable Primary and study completion pushed from Jun 20, 2026 to Jun 20, 2027v21
  3. Minor Enrollment target: 30 to 40
    • Interventions: Carboplatin (Drug), Cemiplimab (Drug), Cetuximab (Drug), Cisplatin (Drug), Docetaxel (Drug), Post-operative radiation therapy (Radiation)… to Carboplatin (Drug), Cemiplimab (Drug), Cetuximab (Drug), Cisplatin (Drug), Docetaxel (Drug), Paclitaxel (Drug), Post-operative radiation…
    • Study arms: 1 to 2
    v14
  4. Minor Study sites: 6 to 7v13
  5. Notable Primary and study completion dates: Jun 20, 2023 to Jun 20, 2026
    • Study sites revised (6)
    v12
Show 8 earlier versionsHide 8 earlier versions
  1. Minor Study sites revised (6)v11
  2. Notable Enrollment target: 10 to 30v10
  3. Notable Trial status: Active, Not Recruiting to Recruiting
    • Site details revised at 6 of 6 sites
    v8
  4. Minor Trial status: Recruiting to Active, Not Recruiting
    • Site details revised at 6 of 6 sites
    v7
  5. Minor Study sites: 5 to 6v6
  6. Minor Study sites revised (5)v4
  7. Minor Study sites: 1 to 5v3
  8. Notable Primary endpoint revisedv2
  1. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Incidence of toxicities graded according to NCI CTCAE
Timeframe: 1 year

Arms and interventions

Head and Neck Squamous Cell Cancer/HNSCCExperimental

Participants with locally advanced, resectable head and neck squamous cell carcinoma for which standard-of-care management would entail definitive surgery followed by adjuvant radiation +/- concurrent chemotherapy are eligible.

Secondary CohortExperimental

Participants with locally advanced, resectable head and neck squamous cell carcinoma for which standard-of-care management would entail definitive surgery followed by adjuvant radiation +/- concurrent chemotherapy are eligible.

Tertiary Cohort: Oral cavity squamous cell carcinoma (OCSCC)Experimental

A tertiary cohort of 20 patients with oral cavity squamous cell carcinoma (OCSCC)

Drugs: Cisplatin, Carboplatin, Docetaxel, Cetuximab, Cemiplimab, Paclitaxel

Procedures: Surgical Resection of Primary +/- Neck Dissection

Radiation: Post-operative radiation therapy

Sites

7 sites in 1 country